Resource Summary Report

Generated by RRID on Aug 9, 2026

Anti-KLRG1-FITC

RRID:AB_2652570
Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-103-640, RRID:AB_2652570

Antibody Information

URL: http://antibodyregistry.org/AB_2652570

Proper Citation: Miltenyi Biotec Cat# 130-103-640, RRID:AB_2652570

Target Antigen: KLRG1

Clonality: monoclonal

Comments: Discontinued: 3-2019; Target Distribution basophils, T cells, NK cells; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-120-425. (RRID:AB_2752091).

Antibody Name: Anti-KLRG1-FITC

Description: This monoclonal targets KLRG1

Target Organism: human

Clone ID: REA261

Antibody ID: AB_2652570

Vendor: Miltenyi Biotec

Catalog Number: 130-103-640

Record Creation Time: 20250819T210507+0000

Record Last Update: 20250819T214745+0000

Ratings and Alerts

No rating or validation information has been found for Anti-KLRG1-FITC.

Warning: Discontinued: 2021
Discontinued: 3-2019; Target Distribution basophils, T cells, NK cells; target type Non-CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-120-425. (RRID:AB_2752091).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Hernández DC, et al. (2021) An in vitro platform supports generation of human innate lymphoid cells from CD34+ hematopoietic progenitors that recapitulate ex vivo identity. Immunity, 54(10), 2417.

Bergamaschi L, et al. (2021) Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity, 54(6), 1257.